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Abstract 
BACKGROUND: Considering the crucial role of appropriate preventative strategies in reducing 
the rate of contrast-induced nephropathy (CIN) occurrence and its related morbidity and 
mortality, the effect of N-acetylcysteine (NAC), ascorbic acid (AA), and normal saline (NS) was 
investigated in the patient’s undergone coronary angiography. 
METHODS: In this clinical trial, 120 patients scheduled for elective coronary angiography with serum 
creatinine (Cr) level > 1.5 mg/dl or glomerular filtration rate (GFR) ≥ 60 selected by convenience 
method. Selected patients were allocated in three treatment groups randomly to receive oral NAC 
(600 mg/twice daily) plus NS (100 ml/hour) (Group A), oral AA (250 mg/twice daily) plus NS (100 
ml/hour) (Group B) and NS (100 ml/hour) (Group C), respectively. The occurrence of CIN was 
evaluated based on serum Cr and GFR in three studied groups, before and after angiography 
procedure. The analysis of variance and paired t-test were used for data analysis by SPSS. 
RESULTS: The serum Cr increased and GFR decreased significantly during the intervention in three 
groups (P < 0.010). However, the amounts of these changes were equal between groups (P > 0.050). 
CONCLUSION: The study showed that nor the addition of NAC neither the addition of AA to 
sodium chloride infusion has more beneficial effect than hydration with sodium chloride, in the 
prevention of CIN. 
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Introduction 
In accordance with increasing cardiovascular 
disease and development of effective diagnostic 
and interventional procedures, the rate of their 
related complications such as contrast induced 
nephropathy (CIN) has been increased.1,2 CIN is 
defined as serum creatinine (Cr) rising in patients 
using intravenous contrast for diagnostic or 
therapeutic procedure.3 The incidence rate of CIN 
in the general population has reported about 2%, 
but is higher in high-risk population with estimate 
rate of 12-50%.4 Though CIN has a benign course 
and in almost all of the cases its related renal 
impairment is transient but it considered as the 
third leading cause of acute renal failure in 
hospitalized patients and is associated with 
increased risk of morbidity, mortality, and medical 
care costs.5,6 The exact mechanism of CIN and its 
related renal impairment has not understood yet. 
Some evidences suggested that factors such as 
increasing level of adenosine, endothelin, and free 
radicals and decreasing level of prostaglandins and 
nitric oxide after using contrast media may result 
in renal hemodynamics impairment, renal tubular 
cells toxicity and consequently renal failure.7-9 
Several preventative strategies including using 
calcium-channel antagonists, atrial natriuretic 
peptide, adenosine antagonists, and dopamine 
have been investigated in this regard, and different 
controversial results have been reported.10,11 Pre-
procedural hydration like an infusion of sodium 
chloride or half saline, considered as one of the 
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most effective strategies for prevention of CIN.12 
Moreover, regarding the fact that one of the 
reported factors in the pathogenesis of CIN are 
oxygen free radical, the concept of using 
antioxidant agents such as N-acetylcysteine (NAC) 
or ascorbic acid (AA) have been developed in the 
treatment of CIN. However, the effectiveness of 
mentioned antioxidants is controversial.13,14 
Previous studies demonstrated that combination 
therapy of NAC and AA had not any additive 
effect in preventing CIN probably due to their 
similar mechanism of oxygen free radical 
scavenging.15 
The role of normal saline (NS) is evaluated in 
several studies and mentioned as a standard strategy 
for prevention of CIN. Additional drugs were 
added to NS for increasing effect of prevention 
strategy; however, results of these studies are 
different and controversial, so it seems that 
additional investigations are needed for detection of 
the best preventive method. Therefore, the aim of 
this study was the evaluation and comparison of the 
effects of two antioxidant agents, including NAC 
and AA plus NS with the traditional approach (NS) 
in preventing of CIN in the patients undergone 
coronary angiography. 
Materials and Methods 
In a randomized clinical trial, 120 patients who 
scheduled for elective coronary angiography were 
enrolled. This study was done in Hajar Hospital, 
Shahrekord, Iran. The study protocol was 
approved by Regional Bioethics Committee of 
Shahrekord University of Medical Sciences 
(Research project number; 934). Iranian 
registration clinical trial (IRCT) number is “IRCT 
2015050722134N1.” Written informed consent 
was obtained from all selected patients. We 
prospectively selected 120 patients with baseline 
Cr level of > 1.5 mg/dl or glomerular filtration 
rate (GFR) ≤ 60. Patients with oliguria  
(< 400 cc/24 hours), severe heart failure with left 
ventricular ejection fraction < 35%, contrast-agent 
hypersensitivity, pregnancy, lactation, acute renal 
failure, IV use of contrast medium within previous 
week, vitamin C supplements use within previous 
week were excluded. Selected patients were 
allocated in three treatment groups randomly to 
receive oral NAC plus NS, (Group A), oral 
ascorbic acid plus NS (Group B) and intravenous 
NS (Group C). Patients of Group A received NAC 
(600 mg) bid (from 24 hours before to 24 hours 
after the procedure) plus NS (100 ml/hour from 
12 hours before to 12 hours after the procedure). 
For Group B patients AA 500 mg (250 mg 12 
hours before and 12 hours after the procedure) 
plus NS (100 ml/hour, 12 hours before to 12 
hours after the procedure) prescribed. Group C 
patients received only NS (100 ml/hour, 12 hours 
before to 12 hours after the procedure). The 
occurrence of CIN and mean of Cr and GFR in 
three studied groups, before and 72 hours after the 
procedure was evaluated and compared. 
CIN defined as increase ≥ 0.5 mg/dl in serum 
Cr or decrease ≥ 25% of GFR after 72 hours. 
Serum Cr was measured using Pars Azmoon 
Diagnostic Kits (Tehran-Iran) by BT 3000 
equipment. GFR was measured using the 
Cockcroft-Gault equation [(140-age) × Body 
Weight/72 × Cr].16 
Data were shown as means ± standard 
deviation. Because the sample size was moderately 
high in each group, so the parametric analysis of 
variance (ANOVA) was used to comparing the 
variables between groups. Paired t-test was used for 
comparing the change of variables during the study. 
Statistical analysis was done by SPSS software 
(version 17, SPSS Inc., Chicago, IL, USA) and  
P < 0.050 were determined as statistically significant. 
Results 
In this clinical trial 120 patients, including 80 
(66.7%) male and 40 (33.3%) female were 
randomly entered in three groups, each one 
including 40 patients. There were 26, 27, and 26 
males in the Group A (oral NAC plus NS), 
Group B (oral AA plus NS) and Group C 
(intravenous NS) respectively. The chi-square test 
did not show any significant difference between 
the distribution of sex in the groups (P = 0.313). 
The overall age of patients was from 38 to 81 
years with the mean of 67.6 ± 8.1 years. The 
mean age of patients in the Groups of A, B, and 
C was 67.5 ± 7.5, 67.8 ± 6.8 and 67.6 ± 8.1 years 
respectively. The ANOVA test did not show any 
significant difference between the age of patients 
in the three groups (P = 0.127). 
The results of serum Cr and GFR in the three 
groups before and after the study was shown in 
table 1. The amount of serum Cr (P = 0.661) and 
GFR (P = 0.785) were equal in the three groups of 
patients at the beginning of the study. The serum Cr 
increased, and GFR decreased significantly during 
the intervention in three groups (Table 1). 
However, the amounts of these changes were equal 
between groups (Table 1). 
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Table 1. Comparison the mean of serum creatinine (Cr) and glomerular filtration rate (GFR) in the three groups before 
and after the study 
 Group A Group B Group C P* (n = 40) (n = 40) (n = 40) 
Cr     
Before intervention 1.68 ± 0.28 1.61 ± 0.36 1.66 ± 0.35 0.661 
After intervention 1.74 ± 0.37 1.69 ± 0.34 1.75 ± 0.36 0.771 
Change 0.06 ± 0.12 0.08 ± 0.14 0.09 ± 0.13 0.716 
P** (before-after) 0.002 0.001 0.001 - 
GFR     
Before intervention 54.80 ± 7.00 55.70 ± 6.00 55.30 ± 5.60 0.785 
After intervention 53.60 ± 7.50 52.90 ± 5.70 52.90 ± 6.70 0.876 
Change -1.22 ± 2.42 -2.75 ± 2.83 -2.45 ± 2.83 0.074 
P** (before-after) 0.003 0.001 0.001 - 
*
 Based on ANOVA test; ** Based on paired t-test; Cr: Creatinine; GFR: Glomerular filtration rate; ANOVA: Analysis of variance 
 
Discussion 
This study showed that adding of NAC and AA 
have not any significant superior effect than 
traditionally used NS for preventing of CIN. 
Though several studies performed in this field, but 
differences in study designs such as patient 
selection, protocol of prophylaxis including dose of 
drugs and its administration form make the 
determination of an optimal approach for the 
prevention of CIN as a challenging issue in this 
field. In this study, the outcome of all three 
administrated regimens was similar. NAC and AA 
as antioxidant agents have not more advantages 
than sodium chloride in preventing CIN. The 
nephroprotective effect of NAC has been reported 
in many studies.17,18 Accordingly the mentioned 
protective effect of NAC is mostly reported in 
patients with higher risk of nephropathy.19 
However, there are controversies regarding the 
effectiveness of NAC in reducing the occurrence of 
CIN in its different doses and type of 
administration. There were also studies which failed 
to confirm the protective effect of NAC in CIN.20,21 
The influence of orally administrated NAC  
(600 mg/twice daily) for CIN prevention first time 
was investigated by Tepel et al.22 They reported that 
administration of oral NAC plus hydration was 
more effective than hydration alone for prevention 
CIN in patients with chronic renal failure using a 
low-osmolality contrast agent. A.C.T investigators23 
in their recent meta-analysis have announced that 
reports regarding the effectiveness of NAC belong 
to smaller clinical trials with an inappropriate 
methodology which tended to overestimate the role 
of NAC in this regard. Similar our results, Ozcan et al. 
have indicated that oral NAC plus hydration therapy 
have not any additional effect than hydration with 
sodium chloride alone.24 
The efficacy of AA for prevention of CIN, 
have been studied both in animal and human 
studies, for example Spargias et al.14 have studied 
the effect of high dose of AA, in 231 patients with 
a serum Cr ≥ 1.2 mg/dl. The mean increase in 
serum Cr level was significantly higher in the 
placebo group than AA group. They concluded 
that prophylactic orally administrated AA may 
have a protective effect for CIN in high-risk 
patients undergoing the coronary procedure. 
Similarly, in a recent study in Slovenia, Dvorsak  
et al.25 reported that AA could have a protective 
role for CIN in patients with mild renal function 
impairment not in those with chronic renal failure. 
Some similar studies have evaluated the 
effectiveness of our studied agents (NAC and AA) 
in preventing CIN among patients undergone 
coronary angiography, and different results have 
reported in this regard. Brueck et al.26 in a 
prospective randomized double-blind placebo 
controlled trial have investigated the effect of NAC 
(600 mg, IV) or AA (500 mg, IV) versus placebo to 
prevent contrast-induced acute kidney injury in 
chronic kidney disease patients (serum Cr ≥ 1.3) 
undergoing elective cardiac catheterization. They 
concluded that standard doses of NAC and AA did 
not prevent CIN in the high-risk patients with non-
ionic, low-osmolality contrast agent. Briguori et al.27 
in the North American synchrophasor initiative 
(NASPI) study, found that NAC was more effective 
than AA in CIN prevention, however, the current 
study did not find the same results. As mentioned 
above there are controversy in the results of studies 
because the different protocol of prevention, the 
dose of drugs, studied population and type of drug 
administration. It seems that prophylactic effect of AA 
is higher in patients with renal insufficiency than 
normal renal function. Regarding the inappropriate 
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preventative effect of AA, factors such as its dose 
which was lower than previous studies or the 
administration form (oral) may explain the controversy 
in findings. Regarding the amount of administrated 
contrast media, as our study was single center and 
there were not any cases with repeated contrast media 
administration, so the effect of the amount of contrast 
agent was similar in all studied groups. In this study, 
we represented a single-center experience among a 
small sample size of patients, which considered the 
limitation of this study. 
Conclusion 
The current study showed that adding of NAC or 
AA to NS infusion had not more beneficial effect. 
Further studies are warranted to evaluate the 
optimal pre-procedural volume repletion or 
appropriate dose of preventative NAC and AA. In 
addition, it is recommended to use more accurate 
laboratory methods such as neutrophil gelatinase-
associated lipocalin or cystatin C in addition to 
serum Cr for early detection of CIN. 
Acknowledgments 
We acknowledge all staff of Hajar Angiography and 
CCU Centers for their cooperation in this study. 
Conflict of Interests 
Authors have no conflict of interests. 
References 
1. Rihal CS, Textor SC, Grill DE, Berger PB, Ting 
HH, Best PJ, et al. Incidence and prognostic 
importance of acute renal failure after percutaneous 
coronary intervention. Circulation 2002; 105(19): 
2259-64. 
2. Davidson CJ, Hlatky M, Morris KG, Pieper K, 
Skelton TN, Schwab SJ, et al. Cardiovascular and 
renal toxicity of a nonionic radiographic contrast 
agent after cardiac catheterization. A prospective 
trial. Ann Intern Med 1989; 110(2): 119-24. 
3. Mehran R, Nikolsky E. Contrast-induced 
nephropathy: definition, epidemiology, and patients 
at risk. Kidney Int Suppl 2006; (100): S11-S15. 
4. Berg KJ. Nephrotoxicity related to contrast media. 
Scand J Urol Nephrol 2000; 34(5): 317-22. 
5. Bagshaw SM, Culleton BF. Contrast-induced 
nephropathy: epidemiology and prevention. 
Minerva Cardioangiol 2006; 54(1): 109-29. 
6. Cavusoglu E, Chhabra S, Marmur JD, Kini A, 
Sharma SK. The prevention of contrast-induced 
nephropathy in patients undergoing percutaneous 
coronary intervention. Minerva Cardioangiol 2004; 
52(5): 419-32. 
7. Murphy SW, Barrett BJ, Parfrey PS. Contrast 
nephropathy. J Am Soc Nephrol 2000; 11(1): 177-82. 
8. Pannu N, Tonelli M. Strategies to reduce the risk of 
contrast nephropathy: an evidence-based approach. 
Curr Opin Nephrol Hypertens 2006; 15(3): 285-90. 
9. Katholi RE, Woods WT, Taylor GJ, Deitrick CL, 
Womack KA, Katholi CR, et al. Oxygen free 
radicals and contrast nephropathy. Am J Kidney 
Dis 1998; 32(1): 64-71. 
10. Kurnik BR, Allgren RL, Genter FC, Solomon RJ, 
Bates ER, Weisberg LS. Prospective study of atrial 
natriuretic peptide for the prevention of 
radiocontrast-induced nephropathy. Am J Kidney 
Dis 1998; 31(4): 674-80. 
11. Stacul F, Adam A, Becker CR, Davidson C, 
Lameire N, McCullough PA, et al. Strategies to 
reduce the risk of contrast-induced nephropathy. 
Am J Cardiol 2006; 98(6A): 59K-77K. 
12. Mueller C, Buerkle G, Buettner HJ, Petersen J, 
Perruchoud AP, Eriksson U, et al. Prevention of 
contrast media-associated nephropathy: randomized 
comparison of 2 hydration regimens in 1620 
patients undergoing coronary angioplasty. Arch 
Intern Med 2002; 162(3): 329-36. 
13. Koc F, Ozdemir K, Kaya MG, Dogdu O, Vatankulu 
MA, Ayhan S, et al. Intravenous N-acetylcysteine 
plus high-dose hydration versus high-dose 
hydration and standard hydration for the prevention 
of contrast-induced nephropathy: CASIS--a 
multicenter prospective controlled trial. Int J 
Cardiol 2012; 155(3): 418-23. 
14. Spargias K, Alexopoulos E, Kyrzopoulos S, Iokovis 
P, Greenwood DC, Manginas A, et al. Ascorbic 
acid prevents contrast-mediated nephropathy in 
patients with renal dysfunction undergoing 
coronary angiography or intervention. Circulation 
2004; 110(18): 2837-42. 
15. Briguori C, Airoldi F, D'Andrea D, Bonizzoni E, 
Morici N, Focaccio A, et al. Renal Insufficiency 
Following Contrast Media Administration Trial 
(REMEDIAL): a randomized comparison of 3 
preventive strategies. Circulation 2007; 115(10): 
1211-7. 
16. Cockcroft DW, Gault MH. Prediction of creatinine 
clearance from serum creatinine. Nephron 1976; 
16(1): 31-41. 
17. Kelly AM, Dwamena B, Cronin P, Bernstein SJ, 
Carlos RC. Meta-analysis: effectiveness of drugs 
for preventing contrast-induced nephropathy. Ann 
Intern Med 2008; 148(4): 284-94. 
18. Shyu KG, Cheng JJ, Kuan P. Acetylcysteine 
protects against acute renal damage in patients with 
abnormal renal function undergoing a coronary 
procedure. J Am Coll Cardiol 2002; 40(8): 1383-8. 
19. Moist L, Sontrop JM, Gallo K, Mainra R, Cutler M, 
  
 
www.mui.ac.ir 15 Jul 
 Contrast-induced nephropathy prevention 
 232     ARYA Atheroscler 2015; Volume 11, Issue 4 
Freeman D, et al. Effect of N-acetylcysteine on 
serum creatinine and kidney function: results of a 
randomized controlled trial. Am J Kidney Dis 
2010; 56(4): 643-50. 
20. Kshirsagar AV, Poole C, Mottl A, Shoham D, 
Franceschini N, Tudor G, et al. N-acetylcysteine for 
the prevention of radiocontrast induced 
nephropathy: a meta-analysis of prospective 
controlled trials. J Am Soc Nephrol 2004; 15(3): 
761-9. 
21. Thiele H, Hildebrand L, Schirdewahn C, Eitel I, 
Adams V, Fuernau G, et al. Impact of high-dose N-
acetylcysteine versus placebo on contrast-induced 
nephropathy and myocardial reperfusion injury in 
unselected patients with ST-segment elevation 
myocardial infarction undergoing primary 
percutaneous coronary intervention. The LIPSIA-
N-ACC (Prospective, Single-Blind, Placebo-
Controlled, Randomized Leipzig Immediate 
PercutaneouS Coronary Intervention Acute 
Myocardial Infarction N-ACC) Trial. J Am Coll 
Cardiol 2010; 55(20): 2201-9. 
22. Tepel M, van der Giet M, Schwarzfeld C, Laufer U, 
Liermann D, Zidek W. Prevention of radiographic-
contrast-agent-induced reductions in renal function by 
acetylcysteine. N Engl J Med 2000; 343(3): 180-4. 
23. Acetylcysteine for prevention of renal outcomes in 
patients undergoing coronary and peripheral 
vascular angiography: main results from the 
randomized Acetylcysteine for Contrast-induced 
nephropathy Trial (ACT). Circulation 2011; 
124(11): 1250-9. 
24. Ozcan EE, Guneri S, Akdeniz B, Akyildiz IZ,
Senaslan O, Baris N, et al. Sodium bicarbonate, N-
acetylcysteine, and saline for prevention of 
radiocontrast-induced nephropathy. A comparison of 
3 regimens for protecting contrast-induced 
nephropathy in patients undergoing coronary 
procedures. A single-center prospective controlled 
trial. Am Heart J 2007; 154(3): 539-44. 
25. Dvorsak B, Kanic V, Ekart R, Bevc S, Hojs R. 
Ascorbic Acid for the prevention of contrast-
induced nephropathy after coronary angiography in 
patients with chronic renal impairment: a 
randomized controlled trial. Ther Apher Dial 2013; 
17(4): 384-90. 
26. Brueck M, Cengiz H, Hoeltgen R, Wieczorek M, 
Boedeker RH, Scheibelhut C, et al. Usefulness of 
N-acetylcysteine or ascorbic acid versus placebo to 
prevent contrast-induced acute kidney injury in 
patients undergoing elective cardiac catheterization: 
a single-center, prospective, randomized, double-
blind, placebo-controlled trial. J Invasive Cardiol 
2013; 25(6): 276-83. 
27. Briguori C, Manganelli F, Scarpato P, Elia PP, 
Golia B, Riviezzo G, et al. Acetylcysteine and 
contrast agent-associated nephrotoxicity. J Am Coll 
Cardiol 2002; 40(2): 298-303. 
 
 
How to cite this article: Khaledifar A, Momeni A, 
Ebrahimi A, Kheiri S, Mokhtari A. Comparison of N-
acetylcysteine, ascorbic acid, and normal saline effect 
in prevention of contrast-induced nephropathy. 
ARYA Atheroscler 2015; 11(4): 228-32. 
 
